Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket



  • OncoCyte Corporation OCX rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.
  • Spruce Biosciences, Inc. SPRB shares rose 84% to $2.30 in pre-market trading. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan.
  • CytomX Therapeutics, Inc. CTMX rose 70.4% to $3.05 in pre-market trading. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics.
  • AMTD Digital Inc. HKD shares rose 40.2% to $42.00 in pre-market trading after surging around 200% on Thursday.
  • Golden Sun Education Group Limited GSUN rose 27% to $1.60 in pre-market trading after jumping around 18% on Thursday.
  • Magic Empire Global Limited MEGL rose 25.2% to $2.88 in pre-market trading after climbing 75% on Thursday.
  • Mobile Global Esports Inc. MGAM rose 17.8% to $1.26 in pre-market trading after gaining over 21% on Thursday.
  • Aethlon Medical, Inc. AEMD shares rose 17.2% to $0.4030 in pre-market trading. Aethlon Medical, last month, posted a Q2 loss of $0.18 per share.
  • eFFECTOR Therapeutics, Inc. EFTR rose 14.2% to $0.63 in pre-market trading after the company issued a clinical data update for Zotatifin.
  • World Wrestling Entertainment, Inc. WWE rose 9.7% to $79.00 in pre-market trading on the news report that the company could be exploring a potential sale. The Wall Street Journal reported that former chief Vince McMahon plans to return to the company.


  • Graphite Bio, Inc. GRPH fell 50.5% to $1.51 in pre-market trading after the company reported voluntary pause of Phase 1/2 CEDAR study of nulabeglogene autogedtemcel for sickle cell disease.
  • Fate Therapeutics, Inc. FATE shares fell 49.1% to $5.60 in pre-market trading after the company reported termination of collaboration agreement with Janssen Biotech, Inc.
  • Virios Therapeutics, Inc. VIRI fell 27.3% to $0.20 in pre-market trading. Virios Therapeutics announced scheduling of FDA meeting in March 2023 to discuss IMC-1 Fibromyalgia Phase 3 program.
  • Acasti Pharma Inc. ACST fell 15.7% to $0.5183 in pre-market trading. Acasti is expected to host conference call on Tuesday, January 10, 2023 to discuss results from recent Phase 1 PK studies for GTX-101 and GTX-102 that met all outcome measures.
  • Vyant Bio, Inc. VYNT fell 14.1% to $1.04 in pre-market trading. Vyant Bio shares jumped around 57% on Thursday after the company engaged LifeSci Capital as its advisor to explore strategic alternatives.
  • ABVC BioPharma, Inc. ABVC fell 13.5% to $0.9250 in pre-market trading. ABVC BioPharma shares climbed over 72% on Thursday after the company announced the FDA approved its IND submission, allowing the company to proceed with the clinical study of ABV-1519 for the treatment of non-small cell lung cancer.
  • Bed Bath & Beyond Inc. BBBY fell 12.4% to $1.48 in pre-market trading after dropping around 30% on Thursday. The company said it will miss its 10-Q filing deadline for the quarter ending Nov 26, 2022 and has also concluded that there is substantial doubt about its ability to continue as a going concern.
  • Oblong, Inc. OBLG fell 11.7% to $2.41 in pre-market trading after gaining around 24% on Thursday. Oblong recently announced a 1-for-15 reverse stock split.
  • InMed Pharmaceuticals Inc. INM fell 10.8% to $1.72 in pre-market trading after declining over 11% on Thursday.
  • Orchard Therapeutics plc ORTX shares fell 9.9% to $0.5674 in pre-market trading. Orchard Therapeutics shares gained around 22% on Thursday after the company announced FDA clearance of the IND application for OTL-203 in MPS-IH.

Read More: Insiders Selling Qualcomm, Skechers And 2 Other Stocks

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapPre-Market OutlookMarketsMoversTrading IdeasPremarket MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!